Skip to main content

Table 2 Characteristics of 4 included studies in this meta-analysis

From: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis

Study

Area

Design

Duration

Criteria for osteoporosis

Duration

Group

Intervention

n

Age, years

Women, n (%)

BMI

Ebina et al. [28]

Japan

Non-RCT

NR

JSBMR

12 months

BP + ELD

MIN 50 mg/month, ELD 0.75 μg/day

80

71.8 ± 0.9

74 (92.5%)

21.3 ± 0.6

BP

MIN 50 mg/month

63

71.7 ± 1.6

58 (92.1%)

21.5 ± 0.6

Iwamoto and Sato [23]

Japan

RCT

April 2012–July 2012

JDC

6 months

BP + ELD

ALE 35 mg weekly or risedronate 17.5 mg weekly, ELD 0.75 μg/day

50

72.3 ± 8.3

50 (100%)

22.5 ± 3.3

BP

ALE 35 mg weekly or risedronate 17.5 mg weekly

46

69.1 ± 9.9

46 (100%)

22.7 ± 2.5

Suzuki et al. [29]

Japan

RCT

May 2016–August 2017

JSBMR

18 months

BP + ELD

MIN 50 mg/month, ELD 0.75 μg/day

14

68.7 ± 3.1

14 (100%)

20.4 ± 0.7

BP

MIN 50 mg/month

14

65.8 ± 4.0

14 (100%)

20.1 ± 0.5

Takeuchi et al. [27]

Japan

Non-RCT

March 2014–January 2017

JDC

12 months

BP + ELD

Ibandronate 1 mg injections, ELD NR

94

NR

NR

NR

BP

Ibandronate 1 mg injections

95

NR

NR

NR

  1. ALE alendronate, MIN minodronate, ELD eldecalcitol, BMI body mass index, BP bisphosphonate, JDC Japanese diagnostic criteria, JSBMR Japanese Society for Bone and Mineral Research, NR not reported, RCT randomized controlled trial